Favorable Media Coverage Somewhat Unlikely to Impact MediciNova (MNOV) Share Price
Press coverage about MediciNova (NASDAQ:MNOV) has trended positive on Wednesday, according to Accern. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MediciNova earned a news impact score of 0.38 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.9925066421997 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Analysts Expect MediciNova, Inc. (MNOV) to Announce ($0.09) Earnings Per Share (americanbankingnews.com)
- MediciNova to Participate in Business Development Panel Session at the BIO Asia International Conference in Tokyo (feeds.benzinga.com)
- MediciNova (MNOV) & The Competition Financial Survey (americanbankingnews.com)
- Brokerages Expect MediciNova, Inc. (MNOV) to Announce ($0.09) EPS (americanbankingnews.com)
MediciNova (NASDAQ MNOV) opened at $13.91 on Wednesday. MediciNova has a 12-month low of $4.40 and a 12-month high of $14.50. The stock has a market capitalization of $512.02, a P/E ratio of -43.47 and a beta of 0.18.
COPYRIGHT VIOLATION WARNING: This article was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.dailypolitical.com/2018/03/14/favorable-media-coverage-somewhat-unlikely-to-impact-medicinova-mnov-share-price.html.
MediciNova Company Profile
Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.